Immuno-Biological Laboratories Co., Ltd.JP:4570
| Mar 31,
2013 | Mar 31,
2014 | Mar 31,
2015 | Mar 31,
2016 | Mar 31,
2017 | Mar 31,
2018 | Mar 31,
2019 | Mar 31,
2020 | Mar 31,
2021 | Mar 31,
2022 | Mar 31,
2023 | Mar 31,
2024 |
|---|
| Profit (loss) before income taxes | 163 | -112 | -161 | -30 | -2,089 | -52 | -164 | -659 | -311 | -250 | -281 | 125 |
|---|
| Depreciation | - | 93 | 96 | 75 | 183 | - | - | - | - | - | - | 2 |
|---|
| Impairment losses | - | - | - | 2 | 735 | 1 | 8 | 0 | 0 | 7 | 1 | 1 |
|---|
| Increase (decrease) in allowance for doubtful accounts | - | - | - | - | - | - | - | - | - | - | 7 | -7 |
|---|
| Interest and dividend income | - | -4 | -4 | -0 | -1 | -1 | -1 | -1 | -0 | -0 | -1 | -0 |
|---|
| Interest expenses | - | 2 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
|---|
| Foreign exchange losses (gains) | - | -2 | -12 | 4 | 1 | 0 | -4 | 1 | -5 | -2 | -2 | -3 |
|---|
| Share of loss (profit) of entities accounted for using equity method | - | - | - | - | - | - | - | 94 | 91 | 153 | 204 | - |
|---|
| Loss (gain) on sale of shares of subsidiaries and associates | - | - | - | - | - | - | - | -16 | - | - | -46 | - |
|---|
| Loss (gain) on valuation of investment securities | - | - | - | 15 | 27 | 2 | - | - | - | - | 2 | 0 |
|---|
| Loss on valuation of shares of subsidiaries and associates | - | - | - | - | - | - | - | - | - | - | 174 | - |
|---|
| Loss on valuation of inventories | - | - | - | - | - | - | - | - | - | - | 15 | - |
|---|
| Surrender value of insurance policies | - | - | - | - | - | - | - | - | -1 | -23 | -5 | -0 |
|---|
| Decrease (increase) in trade receivables | - | 49 | -79 | 29 | 27 | -10 | -6 | 38 | -28 | 25 | -49 | 33 |
|---|
| Decrease (increase) in inventories | - | -24 | -11 | -7 | 1 | -5 | -60 | -7 | 34 | -16 | -6 | -4 |
|---|
| Increase (decrease) in trade payables | - | 8 | -12 | 2 | -5 | 6 | -3 | 0 | 2 | -3 | 2 | -1 |
|---|
| Increase (decrease) in accounts payable - other | - | - | - | - | 10 | 37 | 8 | -25 | -24 | 2 | -1 | 7 |
|---|
| Other, net | - | -15 | 0 | -17 | 34 | 14 | -10 | -8 | 19 | 24 | 21 | -9 |
|---|
| Subtotal | - | 27 | -107 | -14 | -49 | 78 | -239 | -602 | -191 | -84 | 36 | 144 |
|---|
| Interest and dividends received | - | 4 | 5 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 3 |
|---|
| Interest paid | - | -2 | -3 | -2 | -2 | -2 | -1 | -1 | -1 | -1 | -1 | -4 |
|---|
| Income taxes paid | - | -16 | -4 | -2 | -5 | -3 | -4 | -7 | -3 | -8 | -8 | -9 |
|---|
| Net cash provided by (used in) operating activities | - | 12 | -109 | -17 | -56 | 74 | -244 | -609 | -194 | -93 | 26 | 134 |
|---|
| Payments into time deposits and other | - | -62 | -62 | -110 | -117 | -62 | -62 | -62 | -62 | -62 | -62 | -62 |
|---|
| Proceeds from withdrawal of time deposits and other | - | 44 | 68 | 80 | 145 | 56 | 68 | 56 | 68 | 56 | 68 | 56 |
|---|
| Purchase of property, plant and equipment | - | -59 | -57 | -695 | -399 | -1 | - | - | -13 | - | - | -16 |
|---|
| Purchase of intangible assets | - | -2 | -14 | -2 | -3 | - | - | - | - | - | - | -2 |
|---|
| Proceeds from sale of shares of subsidiaries and associates | - | - | - | - | - | - | - | 17 | - | - | 78 | - |
|---|
| Loan advances to subsidiaries and associates | - | - | - | - | - | - | - | - | - | -140 | -55 | - |
|---|
| Other, net | - | -1 | -15 | -0 | -5 | 1 | -1 | -0 | 0 | - | 1 | 0 |
|---|
| Net cash provided by (used in) investing activities | - | -137 | 22 | -608 | -458 | -6 | -593 | 11 | -17 | -156 | 30 | -24 |
|---|
| Net increase (decrease) in short-term borrowings | - | - | -96 | - | - | 10 | 10 | - | - | 105 | 5 | 5 |
|---|
| Proceeds from long-term borrowings | - | - | 400 | - | 330 | - | 30 | - | 50 | 60 | - | 10 |
|---|
| Repayments of long-term borrowings | - | -49 | -138 | -102 | -138 | -146 | -164 | -109 | -66 | -21 | -4 | -14 |
|---|
| Other, net | - | -2 | -2 | 2 | -1 | -2 | -2 | - | - | - | - | - |
|---|
| Net cash provided by (used in) financing activities | - | 465 | 164 | 287 | 2,146 | -138 | -126 | 81 | -216 | 144 | 1 | 1 |
|---|
| Effect of exchange rate change on cash and cash equivalents | - | 2 | 12 | -2 | -1 | -0 | 4 | -1 | 5 | 2 | 2 | 3 |
|---|
| Net increase (decrease) in cash and cash equivalents | - | 342 | 89 | -340 | 1,630 | -71 | -959 | -517 | -422 | -103 | 60 | 113 |
|---|
| Increase (decrease) in cash and cash equivalents resulting from change in scope of consolidation | - | - | 8 | - | - | - | - | - | - | - | 53 | - |
|---|